These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
533 related articles for article (PubMed ID: 22393941)
41. Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention? An industry view. Lynch AS Biochem Pharmacol; 2006 Mar; 71(7):949-56. PubMed ID: 16290174 [TBL] [Abstract][Full Text] [Related]
42. Antibiotic resistance in bacteria associated with food animals: a United States perspective of livestock production. Mathew AG; Cissell R; Liamthong S Foodborne Pathog Dis; 2007; 4(2):115-33. PubMed ID: 17600481 [TBL] [Abstract][Full Text] [Related]
43. Has nature already identified all useful antibacterial targets? Bumann D Curr Opin Microbiol; 2008 Oct; 11(5):387-92. PubMed ID: 18804175 [TBL] [Abstract][Full Text] [Related]
44. Sources of novel antibiotics--aside the common roads. Donadio S; Maffioli S; Monciardini P; Sosio M; Jabes D Appl Microbiol Biotechnol; 2010 Dec; 88(6):1261-7. PubMed ID: 20865256 [TBL] [Abstract][Full Text] [Related]
46. Economics of antibiotic resistance. Sipahi OR Expert Rev Anti Infect Ther; 2008 Aug; 6(4):523-39. PubMed ID: 18662118 [TBL] [Abstract][Full Text] [Related]
47. "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. Huh AJ; Kwon YJ J Control Release; 2011 Dec; 156(2):128-45. PubMed ID: 21763369 [TBL] [Abstract][Full Text] [Related]
48. β-Lactam and glycopeptide antibiotics: first and last line of defense? Jovetic S; Zhu Y; Marcone GL; Marinelli F; Tramper J Trends Biotechnol; 2010 Dec; 28(12):596-604. PubMed ID: 20970210 [TBL] [Abstract][Full Text] [Related]
49. Bacterial cell division as a target for new antibiotics. Sass P; Brötz-Oesterhelt H Curr Opin Microbiol; 2013 Oct; 16(5):522-30. PubMed ID: 23932516 [TBL] [Abstract][Full Text] [Related]
50. How many modes of action should an antibiotic have? Brötz-Oesterhelt H; Brunner NA Curr Opin Pharmacol; 2008 Oct; 8(5):564-73. PubMed ID: 18621146 [TBL] [Abstract][Full Text] [Related]
51. The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time? Vicente M; Hodgson J; Massidda O; Tonjum T; Henriques-Normark B; Ron EZ FEMS Microbiol Rev; 2006 Nov; 30(6):841-52. PubMed ID: 17064283 [TBL] [Abstract][Full Text] [Related]
52. 2012 and beyond: potential for the start of a second pre-antibiotic era? Appelbaum PC J Antimicrob Chemother; 2012 Sep; 67(9):2062-8. PubMed ID: 22687888 [TBL] [Abstract][Full Text] [Related]
53. Exploiting current understanding of antibiotic action for discovery of new drugs. Chopra I; Hesse L; O'Neill AJ Symp Ser Soc Appl Microbiol; 2002; (31):4S-15S. PubMed ID: 12481824 [TBL] [Abstract][Full Text] [Related]
55. Use of constraint-based modeling for the prediction and validation of antimicrobial targets. Trawick JD; Schilling CH Biochem Pharmacol; 2006 Mar; 71(7):1026-35. PubMed ID: 16329998 [TBL] [Abstract][Full Text] [Related]
56. The antibiotic resistance crisis, with a focus on the United States. Martens E; Demain AL J Antibiot (Tokyo); 2017 May; 70(5):520-526. PubMed ID: 28246379 [TBL] [Abstract][Full Text] [Related]